Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF V600 Mutation”

93 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 93 results

Testing effectiveness (Phase 2)Ended earlyNCT04488003
What this trial is testing

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

Who this might be right for
Advanced Solid TumorBRAF Gene MutationBRAF Gene Alteration+6 more
BioMed Valley Discoveries, Inc 104
Testing effectiveness (Phase 2)UnknownNCT05102292
What this trial is testing

The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Who this might be right for
Anaplastic Thyroid CancerATC
Shanghai Henlius Biotech 25
Testing effectiveness (Phase 2)UnknownNCT03514901
What this trial is testing

To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

Who this might be right for
Melanoma MetastaticBRAF V600 Mutation
Intergruppo Melanoma Italiano 120
Early research (Phase 1)Study completedNCT01738451
What this trial is testing

Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

Who this might be right for
Cancer
GlaxoSmithKline 50
Early research (Phase 1)Ended earlyNCT03332589
What this trial is testing

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

Who this might be right for
Malignant MelanomaBrain Metastases
Spirita Oncology, LLC 4
Post-approval studies (Phase 4)Looking for participantsNCT03340506
What this trial is testing

Dabrafenib and/or Trametinib Rollover Study

Who this might be right for
MelanomaNon Small Cell Lung CancerSolid Tumor+2 more
Novartis Pharmaceuticals 100
Early research (Phase 1)Study completedNCT01910181
What this trial is testing

Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 46
Testing effectiveness (Phase 2)Study completedNCT02684058
What this trial is testing

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Who this might be right for
Diffuse AstrocytomaAnaplastic AstrocytomaAstrocytoma+19 more
Novartis Pharmaceuticals 151
Large-scale testing (Phase 3)Not Yet RecruitingNCT07440290
What this trial is testing

DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

Who this might be right for
Haematological MalignancyMalignant NeoplasmLymphoproliferative Disorders+16 more
Cancer Research UK 30
Early research (Phase 1)WithdrawnNCT04759846
What this trial is testing

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Who this might be right for
BRAF V600 MutationUnresectable MelanomaMetastatic Melanoma+1 more
Pierre Fabre Medicament
Early research (Phase 1)UnknownNCT03781219
What this trial is testing

A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation

Who this might be right for
Solid Tumor
Shanghai Kechow Pharma, Inc. 45
Large-scale testing (Phase 3)Study completedNCT03551626
What this trial is testing

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes

Who this might be right for
Malignant Melanoma
Novartis Pharmaceuticals 552
Early research (Phase 1)Ended earlyNCT05501912
What this trial is testing

ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorBRAF V600 Mutation
ABM Therapeutics Shanghai Company Limited 20
Early research (Phase 1)Looking for participantsNCT04903119
What this trial is testing

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Who this might be right for
Metastatic MelanomaBRAF Gene Mutation
Rina Plattner 30
Testing effectiveness (Phase 2)Study completedNCT03220035
What this trial is testing

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Childhood Non-Hodgkin LymphomaAnn Arbor Stage IV Childhood Non-Hodgkin Lymphoma+20 more
National Cancer Institute (NCI) 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT01972347
What this trial is testing

Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma

Who this might be right for
Melanoma
Melanoma Institute Australia 35
Not applicableStudy completedNCT01804140
What this trial is testing

A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

Who this might be right for
Multiple Myeloma, Neoplasms
Genentech, Inc. 662
Early research (Phase 1)Looking for participantsNCT06536400
What this trial is testing

Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

Who this might be right for
Solid Tumors
Haisco Pharmaceutical Group Co., Ltd. 316
Not applicableActive Not RecruitingNCT04666272
What this trial is testing

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

Who this might be right for
Melanoma
Novartis Pharmaceuticals 78
Testing effectiveness (Phase 2)Study completedNCT01286753
What this trial is testing

Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

Who this might be right for
Neoplasms
Hoffmann-La Roche 51
Load More Results